PAVmed Inc. Files 8-K Report

TL;DR

PAVM filed a standard 8-K on 9/11/25, no major news.

AI Summary

On September 11, 2025, PAVmed Inc. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing serves as a routine update for investors, confirming the company's ongoing reporting obligations with the SEC.

Risk Assessment

Risk Level: low — This is a routine filing with no new material information that would immediately impact the company's risk profile.

Key Players & Entities

• PAVmed Inc. (company) — Registrant
• September 11, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 360 Madison Avenue, 25th Floor, New York, New York 10017 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, Par Value $0.001 Per Share PAVM The Nasdaq Stock Mar
• $1.00 — iagnostics' common stock, at a price of $1.00 per share, in its previously announced
• $26.9 million — ering, are expected to be approximately $26.9 million. Lucid Diagnostics intends to use the n

Filing Documents

• form8-k.htm (8-K) — 42KB
• 0001493152-25-013048.txt ( ) — 246KB
• pavm-20250911.xsd (EX-101.SCH) — 4KB
• pavm-20250911_def.xml (EX-101.DEF) — 26KB
• pavm-20250911_lab.xml (EX-101.LAB) — 36KB
• pavm-20250911_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2025 PAVMED INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37685 47-1214177 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 360 Madison Avenue , 25th Floor , New York , New York 10017 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (917) 813-1828 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.001 Per Share PAVM The Nasdaq Stock Market LLC Series Z Warrants to Purchase Common Stock PAVMZ The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01. Other Events. On September 11, 2025, Lucid Diagnostics Inc. (the " Lucid Diagnostics "), a subsidiary of PAVmed Inc. (the " Company "), closed on the sale of 28,750,000 shares (the " Shares ") of Lucid Diagnostics' common stock, at a price of $1.00 per share, in its previously announced underwritten offering to the public (the " Offering "). The Shares include 3,750,000 shares of Lucid Diagnostics' common stock subject to the underwriters' option, which was exercised in full at the closing. The net proceeds from the Offering, after deducting the underwriting discount and other estimated expenses of the Offering, are expected to be approximately $26.9 million. Lucid Diagnostics intends to use the net proceeds from the Offering for working capital and general corporate purposes. The Offering was made pursuant to Lucid Diagnostics' existing shelf registration statement on Form S-3 (Registration No. 333-268560) and a prospectus supplement thereto dated September 10, 2025. The Offering, including the related agreements, are described in more detail in the Current Reports on Form 8-K filed with the SEC by Lucid Diagnostics on September 10, 2025 and September 11, 2025, and such description is incorporated herein by reference. Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 11, 2025 PAVMED INC. By: /s/ Dennis McGrath Dennis McGrath President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR